TruScient
dibotermin alfa
Table of contents
Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for TruScient has been withdrawn at the request of the marketing authorisation holder.
This EPAR was last updated on 03/02/2015
Authorisation details
| Product details | |
|---|---|
| Name |
TruScient
|
| Agency product number |
EMEA/V/C/002000
|
| Active substance |
dibotermin alfa
|
| International non-proprietary name (INN) or common name |
dibotermin alfa
|
| Species |
Dogs
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QM05BC01
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Zoetis Belgium SA
|
| Revision |
4
|
| Date of issue of marketing authorisation valid throughout the European Union |
14/12/2011
|
| Contact address |
Rue Laid Burnait, 1
1348 Louvain-la-Neuve Belgium |
Product information
15/01/2015 TruScient - EMEA/V/C/002000 - IAIN/0005/G
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Pharmacotherapeutic group
Bone morphogenetic proteins
Therapeutic indication
Therapeutic indication
Osteoinductive agent for use in the treatment of long-bone fractures as an adjunct to standard surgical care using open fracture reduction in dogs.